稳定期慢性阻塞性肺疾病患者血清可溶性髓样细胞触发受体－1的检测及临床意义

摘要

Objective To determine the value of soluble triggering receptor expressed on myeloid cells 1 (sTREM-1) in patients with stable chronic obstructive pulmonary disease (sCOPD). Methods From 2015 January to 2015 August, 101 patients with stable chronic obstructive pulmonary disease and 81 healthy controls were en-rolled. All subjects underwent pulmonary function test to record FEV1%pred and FEV1%FVC and their serum sTREM-1 levels were determined. Arterial blood gas analyses and COPD assessment tests were also conducted in stable COPD patients. Results Serum sTREM-1 levels were significantly higher in stable COPD patients than healthy controls (113.2 ± 31.5 pg/mL and 83.8 ± 17.9 pg/mL respectively, P=0.000). sTREM-1 levels were posi-tively correlated with CAT score (r=0.507, P=0.000), whereas negatively correlated with FEV1%pred and PaO2 (r = 0.507, P = 0.000; r = 0.439, P = 0.000). Conclusion sTREM-1 is a promising biomarker to evaluate sCOPD in the future.%目的：探讨可溶性髓样细胞触发受体－1（sTREM-1）对稳定期慢性阻塞性肺疾病（sCOPD）病情的评估作用。方法：选取2015年1月至2015年8月于我院就诊的sCOPD患者101例作为观察组，同期选取健康查体者81例作为对照组。所有研究对象均行肺功能检查记录 FEV1％pred、采集外周静脉血检测血清sTREM-1；对sCOPD患者进行动脉血气分析与COPD患者自我评估测试（CAT）。结果：sCOPD组血清sTREM-1水平显著高于对照组[（113．2±31．5） pg／mL vs．（83．8±17．9） pg／mL， P＝0．000]。 sCOPD患者血清sTREM-1水平与CAT评分呈正相关（r＝0．507， P＝0．000），与PaO2、FEV1％pred呈显著负相关（r＝－0．439， P ＝0．000；r ＝－0．560， P ＝0．000）。结论：血清sTREM-1具有评估sCOPD患者严重程度的潜在价值。